Dr. Martee Hensley on Trabectedin as a Treatment for Uterine Leiomyosarcoma

Martee Hensley, MD
Published: Monday, Mar 21, 2016



Martee Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the introduction of trabectedin into the armamentarium for uterine leiomyosarcoma. Hensley says the FDA approval for the treatment requires patients to have had a prior anthracycline therapy, and the treatment will likely fall into the third- or fourth-line of treatment for the malignancy. She adds that trabectedin may fall into the fourth-line due to treatments such as pazopanib currently occupying the third-line.
 
Hensley says the current treatment paradigm for uterine leiomyosarcoma has combinations such as docetaxel and gemcitabine, which achieve around a 30% objective response rate. She adds that another efficacious treatment within the carcinoma is doxorubicin.


Martee Hensley, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the introduction of trabectedin into the armamentarium for uterine leiomyosarcoma. Hensley says the FDA approval for the treatment requires patients to have had a prior anthracycline therapy, and the treatment will likely fall into the third- or fourth-line of treatment for the malignancy. She adds that trabectedin may fall into the fourth-line due to treatments such as pazopanib currently occupying the third-line.
 
Hensley says the current treatment paradigm for uterine leiomyosarcoma has combinations such as docetaxel and gemcitabine, which achieve around a 30% objective response rate. She adds that another efficacious treatment within the carcinoma is doxorubicin.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x